Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients | Zendy

Noha N. Salama | Zendy; Jonathan H. Segal | Zendy; Mariann D. Churchwell | Zendy; J.H. Patel | Zendy; Lihong Gao | Zendy; Michael Heung | Zendy; Bruce A. Mueller | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients

Author(s) -

Noha N. Salama,

Jonathan H. Segal,

Mariann D. Churchwell,

J.H. Patel,

Lihong Gao,

Michael Heung,

Bruce A. Mueller

Publication year - 2009

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfp655

Subject(s) - daptomycin , medicine , pharmacokinetics , dosing , hemodialysis , trough level , urology , pharmacology , transplantation , staphylococcus aureus , vancomycin , tacrolimus , biology , bacteria , genetics

Daptomycin has concentration-dependent antibacterial activity against Gram-positive bacteria. Its use is increasing in haemodialysis units. The manufacturer recommends a 4-6-mg/kg dose administered every 48 hrs for patients receiving haemodialysis. However, there are no published data about daptomycin pharmacokinetics and clearance during haemodialysis. The recommended dosing regimen would conflict with asymmetric thrice-weekly haemodialysis, which yields two ~44-hr and one ~68-hr interdialytic periods. This is the first study to evaluate daptomycin pharmacokinetics in haemodialysis patients, assess the extent of daptomycin dialytic removal and model serum concentrations at 44 and 68 hrs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research